BACKGROUND: Vascular closure devices are designed to obtain a fast hemostasis of the vascular access site after diagnostic and interventional procedures. This result should be obtained with a low incidence of complications. METHODS: A retrospective, non-randomized study was performed to evaluate the success rate and vascular complications associated with the use of two different vascular sealing devices [Angio-Seal (Daig Corporation, Minnetonka, Minnesota) and Prostar (Perclose, Inc., Redwood City, California)] after interventional procedures. RESULTS: Eight-hundred and twenty-seven devices were used (245 Angio-Seal and 582 Prostar). Angio-Seal success rate was 92% with a 2.5% rate of vascular complications; Prostar success rate was 89% with a 3.4% rate of vascular complications. Multivariate logistic regression analysis identified advanced age (p < 0.05) and lower weight (p < 0.05) as independent predictors of vascular complications associated with Angio-Seal use, while diabetes (p < 0.05) was found to be a predictor of vascular complications in the Prostar group. Abciximab use and larger sheath size were not associated with an increased probability of vascular complications. CONCLUSION: Angio-Seal and Prostar obtain a fast vascular access hemostasis after interventional procedures, with a low incidence of major vascular complications.
BACKGROUND: Vascular closure devices are designed to obtain a fast hemostasis of the vascular access site after diagnostic and interventional procedures. This result should be obtained with a low incidence of complications. METHODS: A retrospective, non-randomized study was performed to evaluate the success rate and vascular complications associated with the use of two different vascular sealing devices [Angio-Seal (Daig Corporation, Minnetonka, Minnesota) and Prostar (Perclose, Inc., Redwood City, California)] after interventional procedures. RESULTS: Eight-hundred and twenty-seven devices were used (245 Angio-Seal and 582 Prostar). Angio-Seal success rate was 92% with a 2.5% rate of vascular complications; Prostar success rate was 89% with a 3.4% rate of vascular complications. Multivariate logistic regression analysis identified advanced age (p < 0.05) and lower weight (p < 0.05) as independent predictors of vascular complications associated with Angio-Seal use, while diabetes (p < 0.05) was found to be a predictor of vascular complications in the Prostar group. Abciximab use and larger sheath size were not associated with an increased probability of vascular complications. CONCLUSION: Angio-Seal and Prostar obtain a fast vascular access hemostasis after interventional procedures, with a low incidence of major vascular complications.
Authors: Adam M Falcone; Rahul Bose; Robert C Stoler; Michael Kim; Emily Laible; Lucy Kang; Kim Waters; Janet Dunkerley; James W Choi Journal: Proc (Bayl Univ Med Cent) Date: 2011-07
Authors: Ha Young Kim; Sung Wook Choo; Hong Gee Roh; Heon Han; Sam Soo Kim; Ji Yeon Lee; Yul Ri Park; Sung Hoon Lee; Sung Wook Shin; Kwang Bo Park; Young Soo Do; Sung Ki Cho; In Ho Lee; Sung Mok Kim; Hong Sik Byun; Pyoung Jeon Journal: Korean J Radiol Date: 2006 Jan-Mar Impact factor: 3.500